Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost- effective treatment of refractory angina. A phase II randomized, double-blinded, placebo-controlled study.
Conditions
Brief summary
Improvement of functional capacity using 6-minute walking test, Improvement of symptoms assessed by Canadian Cardiovascular Society (CCS) class
Detailed description
Improvement of functional capacity using 6-minute walking test, Improvement of symptoms assessed by Canadian Cardiovascular Society (CCS) class, Increase in myocardial perfusion
Interventions
DRUGAdsVEGF-D Delta N Delta C
DRUGPlacebo to AdsVEGF-D Delta N Delta C test product
Sponsors
Pohjois-Savon hyvinvointialue
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of functional capacity using 6-minute walking test, Improvement of symptoms assessed by Canadian Cardiovascular Society (CCS) class | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of functional capacity using 6-minute walking test, Improvement of symptoms assessed by Canadian Cardiovascular Society (CCS) class, Increase in myocardial perfusion | — |
Countries
Denmark, Finland
Outcome results
None listed